Evidence map›Paper›PMID 34618685›Full record

ArticleJCI insight2021

Microglia regulate brain progranulin levels through the endocytosis/lysosomal pathway.

Tingting Dong, Leon Tejwani, Youngseob Jung, Hiroshi Kokubu, Kimberly Luttik, Terri M Driessen, Janghoo Lim

Abstract read
In one paragraph

Article in JCI insight, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Progranulin released from microglial lysosomes reduces neuronal ferroptosis after cerebral ischemia in mice.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023
    Article
  7. Preclinical Interventions in Mouse Models of Frontotemporal Dementia Due to Progranulin Mutations.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tingting DongDepartment of Genetics, Yale School of Medicine, New Haven, Connecticut, USA.
Leon TejwaniInterdepartmental Neuroscience Program, Yale University, New Haven, Connecticut, USA.
Youngseob JungDepartment of Genetics, Yale School of Medicine, New Haven, Connecticut, USA.
Hiroshi KokubuDepartment of Genetics, Yale School of Medicine, New Haven, Connecticut, USA.
Kimberly LuttikInterdepartmental Neuroscience Program, Yale University, New Haven, Connecticut, USA.
Terri M DriessenDepartment of Genetics, Yale School of Medicine, New Haven, Connecticut, USA.
Janghoo LimDepartment of Genetics, Yale School of Medicine, New Haven, Connecticut, USA.

Funding

NEUROBIOLOGY OF CORTICAL SYSTEMST32NS007224 · NINDS · YALE UNIVERSITY · PI CARDIN, JESSICA A · 1985 to 2025
$4.6M
Evaluation of a novel NLK function in lysosome biogenesis and neurodegenerative diseasesR01AG074609 · NIA · YALE UNIVERSITY · PI LIM, JANGHOO · 2021 to 2025
$4.0M
Microglial regulation of Progranulin levelsR01AG066447 · NIA · YALE UNIVERSITY · PI LIM, JANGHOO · 2020 to 2024
$3.1M
Cellular and Molecular Studies of SBMA Neuromuscular DiseaseR01NS088321 · NINDS · YALE UNIVERSITY · PI LIM, JANGHOO · 2015 to 2019
$2.2M
Investigating the Pathogenesis of Cerebellar NeurodegenerationR01NS083706 · NINDS · YALE UNIVERSITY · PI LIM, JANGHOO · 2014 to 2018
$1.8M
The role of TRIO signaling in neuronal development, synaptic function, and circuit connectivityR56MH122449 · NIMH · YALE UNIVERSITY · PI CARDIN, JESSICA A, HIGLEY, MICHAEL JAMES · 2021 to 2022
$1.4M
Regulation of inhibitory interneuron developmentR21MH119803 · NIMH · YALE UNIVERSITY · PI LIM, JANGHOO · 2019 to 2020
$461k
NIA NIH HHS R01 AG066447NIA NIH HHS R01 AG074609NIMH NIH HHS R21 MH119803NIMH NIH HHS R56 MH122449NINDS NIH HHS R01 NS083706NINDS NIH HHS R01 NS088321NINDS NIH HHS T32 NS007224
6 · The paper itself

Abstract

Genetic variants in Granulin (GRN), which encodes the secreted glycoprotein progranulin (PGRN), are associated with several neurodegenerative diseases, including frontotemporal lobar degeneration, neuronal ceroid lipofuscinosis, and Alzheimer's disease. These genetic alterations manifest in pathological changes due to a reduction of PGRN expression; therefore, identifying factors that can modulate PGRN levels in vivo would enhance our understanding of PGRN in neurodegeneration and could reveal novel potential therapeutic targets. Here, we report that modulation of the endocytosis/lysosomal pathway via reduction of Nemo-like kinase (Nlk) in microglia, but not in neurons, can alter total brain Pgrn levels in mice. We demonstrate that Nlk reduction promotes Pgrn degradation by enhancing its trafficking through the endocytosis/lysosomal pathway, specifically in microglia. Furthermore, genetic interaction studies in mice showed that Nlk heterozygosity in Grn haploinsufficient mice further reduces Pgrn levels and induces neuropathological phenotypes associated with PGRN deficiency. Our results reveal a mechanism for Pgrn level regulation in the brain through the active catabolism by microglia and provide insights into the pathophysiology of PGRN-associated diseases.

Indexed as

AnimalsDisease Models, AnimalEndocytosisHumansLysosomesMiceMicrogliaProgranulinsProgranulinsDementiaMouse modelsNeurodegenerationNeuroscience

Identifiers

PMID34618685
PMCPMC8663778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.